The Prognostic Impact of Circulating Tumour DNA in Melanoma Patients Treated with Systemic Therapies—Beyond BRAF Mutant Detection

SIMPLE SUMMARY: Circulating tumour DNA (ctDNA) has been shown to be an informative biomarker in melanoma. Here we analysed plasma ctDNA in a real-world metastatic melanoma cohort. We found the kinetics of ctDNA decline are delayed in patients treated with immunotherapy compared to those receiving MA...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancers (Basel)
Main Authors: Marsavela, Gabriela, Johansson, Peter A., Pereira, Michelle R., McEvoy, Ashleigh C., Reid, Anna L., Robinson, Cleo, Warburton, Lydia, Khattak, Muhammad A., Meniawy, Tarek M., Amanuel, Benhur, Millward, Michael, Hayward, Nicholas K., Ziman, Melanie R., Gray, Elin S., Calapre, Leslie
Formato: Artigo
Idioma:Inglês
Publicado: MDPI 2020
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7765660/
https://ncbi.nlm.nih.gov/pubmed/33339135
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12123793
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares